Takeda Files 9-Month Financials Ending Dec 31, 2023
Ticker: TKPHF · Form: 6-K · Filed: Feb 1, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-report, quarterly-results, international-filing
TL;DR
**Takeda just dropped its Q3 financials, giving us a fresh look at their money situation.**
AI Summary
Takeda Pharmaceutical Company Limited filed a 6-K on February 1, 2024, to provide its Summary of Financial Statements for the nine-month period ended December 31, 2023. This filing, signed by Chief Accounting Officer Norimasa Takeda, includes an English translation of the financial summary and a financial appendix. This matters to investors because it offers a crucial, recent look into the company's financial health and performance, allowing them to assess its profitability and stability over the past three quarters.
Why It Matters
This filing provides investors with the latest financial performance data for Takeda, essential for evaluating the company's operational efficiency and overall financial health.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not inherently introduce new risks, but rather provides data to assess existing financial risks.
Analyst Insight
A smart investor would review the detailed financial statements included as exhibits to this 6-K to understand Takeda's revenue, expenses, and profitability trends for the nine months ended December 31, 2023, and compare these figures to previous periods and analyst expectations.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — registrant filing the 6-K
- Norimasa Takeda (person) — Chief Accounting Officer and Corporate Controller who signed the filing
- Christophe Web (person) — Representative of Takeda Pharmaceutical Company Limited
FAQ
What is the purpose of this 6-K filing by Takeda Pharmaceutical Company Limited?
The purpose of this 6-K filing is to submit the 'Summary of Financial Statements for the Nine-month Period Ended December 31, 2023' (IFRS, Consolidated), along with a Financial Appendix, as required for foreign private issuers.
Who signed this 6-K filing on behalf of Takeda Pharmaceutical Company Limited?
The 6-K filing was signed by Norimasa Takeda, who holds the title of Chief Accounting Officer and Corporate Controller for Takeda Pharmaceutical Company Limited, on February 1, 2024.
What period do the financial statements covered in this filing pertain to?
The financial statements covered in this filing are for the nine-month period ended December 31, 2023.
What is Takeda Pharmaceutical Company Limited's stock exchange listing and TSE Code?
Takeda Pharmaceutical Company Limited is listed on the Tokyo, Nagoya, Fukuoka, and Sapporo stock exchanges, with a TSE Code of 4502.
What specific exhibits are included in this 6-K filing?
This 6-K filing includes two exhibits: Exhibit 1, which is the (English Translation) Summary of Financial Statements for the Nine-month Period Ended December 31, 2023, and Exhibit 99.1, which is the Financial Appendix.
Filing Stats: 4,578 words · 18 min read · ~15 pages · Grade level 7.6 · Accepted 2024-02-01 06:06:39
Filing Documents
- form6k-1_020124.htm (6-K) — 716KB
- exhibit991_020124.htm (EX-99.1) — 750KB
- image.jpg (GRAPHIC) — 8KB
- 0001395064-24-000011.txt ( ) — 1478KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date February 1, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Summary of Financial Statements for the Nine-month Period Ended December 31, 2023 (IFRS, Consolidated) February 1, 2024 Takeda Pharmaceutical Company Limited Stock exchange listings Tokyo, Nagoya, Fukuoka, Sapporo TSE Code 4502 URL httpswww.takeda.com Representative Christophe Weber, President CEO Contact Christopher O'Reilly Telephone +81-3-3278-2306 Email takeda.ir.contacttakeda.com Global Head of IR, Global Finance Scheduled date of securities report submission February 2, 2024 Scheduled date of dividend payment commencement - Supplementary materials for the financial statements Yes Presentation to explain the financial statements Yes (Million JPY, rounded to the nearest million) 1. Consolidated Financial Results for the Nine-month Period Ended December 31, 2023 (April 1 to December 31, 2023 ) (1) Consolidated Operating Results (year to date) (Percentage figures represent changes over the same period of the previous year) Revenue Operating profit Profit before tax Net profit for the period (Million JPY) (%) (Million JPY) (%) (Million JPY) (%) (Million JPY) (%) Nine-month Period Ended December 31, 2023 3,212,893 4.6 224,144 (44.2) 100,313 (69.3) 147,191 (48.5) Nine-month Period Ended December 31, 2022 3,071,322 13.9 401,943 (13.1) 327,175 (8.3) 285,903 18.4 Net profit attributable to income for the period Basic earnings per share Diluted earnings per share (Million JPY) (%) (Million JPY) (%) (JPY) (JPY) Nine-month Period Ended December 31, 2023 147,085 (48.6) 625,154 (16.7) 94.10 93.17 Nine-month Period Ended December 31, 2022 285,883 18.4 750,209